Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)

被引：0
|
作者：
Strik, A. [1 ]
van de Vrie, W. [2 ]
Bloemsaat-Minekus, J. [3 ]
Nurmohamed, M. [4 ]
Bossuyt, P. [5 ]
Bodelier, A. [6 ]
Rispens, T. [7 ]
van Megen, Y. [3 ]
D'Haens, G. [1 ]
机构：
[1] Acad Med Ctr, Gastroenterol & Hepatol, Amsterdam, Netherlands
[2] Albert Schweitzer Hosp, Dept Gastroenterol & Hepatol, Dordrecht, Netherlands
[3] Mundipharma Pharmaceut BV, Hoevelaken, Netherlands
[4] Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands
[5] Imelda Hosp, Bonheiden, Belgium
[6] Amphia Hosp Breda Loc Langendijk, Breda, Netherlands
[7] Tytgat Inst Intestinal & Liver Res, AMC, Amsterdam, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P724
引用
收藏
页码：S477 / S478
页数：2
相关论文
共 50 条
  • [31] Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients
    Jahnsen, Jorgen
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 322 - 329
  • [32] Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
    Pierik, Marieke J.
    van der Meulen, Andrea E.
    van der Linde, Klaas
    Lutgens, Maurice
    Kuijvenhoven, Johan P.
    Akol, Halil
    Klompmaker, Ids J.
    Sikkens, Michelle S. G.
    van Megen, Yvonne J. B.
    Stoop, Corinne M.
    Bloemsaat-Minekus, Joanne P. J.
    Dijkstra, Gerard
    CROHNS & COLITIS 360, 2022, 4 (03)
  • [33] DISEASE WORSENING AND SAFETY IN PATIENTS SWITCHING FROM ORIGINATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN THE RANDOMIZED NOR-SWITCH-STUDY: EXPLORATIVE ANALYSIS IN SPA PATIENTS
    Goll, G. L.
    Olsen, I. C.
    Bolstad, N.
    Jorgensen, K. K.
    Lorentzen, M.
    Mork, C.
    Jahnsen, J.
    Haavardsholm, E. A.
    Kvien, T. K.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 338 - 339
  • [34] SAFETY AND EFFICACY OF INFLIXIMAB BIOSIMILAR SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE WHO UNDERWENT A SWITCH FROM INFLIXIMAB BIOSIMILAR CT-P13
    Lovero, R.
    Losurdo, G.
    Biscaglia, G.
    Valvano, M. R.
    Biancofiore, A.
    Martino, G.
    Nardella, M.
    Andriulli, A.
    Principi, M.
    Bossa, F.
    DIGESTIVE AND LIVER DISEASE, 2019, 51 : E227 - E227
  • [35] Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar
    Mahmmod, S.
    Schultheiss, J. P. D.
    Tan, A. C. I. T. L.
    Lutgens, M. W. M. D.
    Gilissen, L. P. L.
    Mahmmod, N.
    van der Meulen-de Jong, A. E.
    Dijkstra, G.
    van Bodegraven, A. A.
    Oldenburg, B.
    Fidder, H. H.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S316 - S317
  • [36] Effectiveness and safety of switching patients with inflammatory bowel disease from originator infliximab to CT-P13: systematic review and meta-analysis
    Hanzel, J.
    Strik, A.
    Gecse, K.
    D'Haens, G.
    Dreesen, E.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S367 - S368
  • [37] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Srinivasan, Ashish
    Haifer, Craig
    Thin, Lena
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 215 (09) : 435 - 435
  • [38] Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance
    Scherlinger, Marc
    Germain, Vincent
    Labadie, Celine
    Barnetche, Thomas
    Truchetet, Marie-Elise
    Bannwarth, Bernard
    Mehsen-Cetre, Nadia
    Richez, Christophe
    Schaeverbeke, Thierry
    JOINT BONE SPINE, 2018, 85 (05) : 561 - 567
  • [39] Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study
    Hellstrom, Per M.
    Gemmen, Eric
    Ward, Heather A.
    Koo, Hyewon
    Faccin, Freddy
    Xue, Zhenyi
    Malmborg, Petter
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (12) : 1435 - 1442
  • [40] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Lim, David
    Bandiera, Rhiannon
    Handsley, Elizabeth
    MEDICAL JOURNAL OF AUSTRALIA, 2021,
12345